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Abstract
The application of microbubbles and ultrasound to deliver nanoparticle carriers for drug and gene
delivery is an area that has expanded greatly in recent years. Under ultrasound exposure,
microbubbles can enhance nanoparticle delivery by increasing cellular and vascular permeability.
In this review, the underlying mechanisms of enhanced nanoparticle delivery with ultrasound and
microbubbles and various proposed delivery techniques are discussed. Additionally, types of
nanoparticles currently being investigated in preclinical studies, as well as the general limitations
and benefits of a microbubble-based approach to nanoparticle delivery are reviewed.
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Introduction
The use of ultrasound microbubble contrast agents has expanded beyond their primary role
in diagnostics and into the research fields of drug and gene therapy [1-4]. Originally
approved for use in echocardiography, microbubble contrast agents are encapsulated
gaseous microspheres that improve the quality of ultrasound images due to the difference in
acoustic impedance between their gaseous core and the surrounding medium and due to their
nonlinear oscillation in an acoustic field [1-5]. The shells of the microbubbles are composed
of materials such as proteins, polymers, or lipids, while the gas core is typically a high
molecular weight gas such as a perfluorocarbon or sulfur hexafluoride [6]. Microbubbles
have been utilized for imaging myocardial perfusion [7, 8], left ventricular opacification [9,
10], blood-perfusion in tumors [11, 12], liver [13], and kidney [14], and for molecular
targeting of angiogenesis [15, 16]or inflammation [17, 18].
Ultrasound is widely used in the clinic because it is safe, inexpensive, and portable.
Additionally, ultrasound has the ability to focus deep within tissue, which can be taken
advantage of for therapeutic applications. Ultrasound, without the aid of microbubbles, is
well established to have therapeutic uses in the areas of hyperthermia [19, 20], tissue
ablation [21, 22], lithotripsy [23, 24], and thrombolysis [25-27]. When microbubbles are
combined with ultrasound for therapy, the applications extend into fields of drug and gene
delivery [27-32], and particularly chemotherapy [1, 33].
The development of a drug or gene delivery method that could target a tumor or organ with
high specificity and improve therapeutic efficacy, while reducing side effects, is of
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particular interest to many areas of medicine [34, 35]. The combination of ultrasound
technology and nanoparticle drug capabilities has developed into a promising method of
achieving targeted drug delivery. In this review, we discuss the underlying mechanisms of
nanoparticle delivery with ultrasound and microbubbles, and assess various proposed
delivery techniques. Additionally, we examine the types of nanoparticles currently being
investigated in preclinical studies, as well as the general limitations and benefits of a
microbubble-based approach to nanoparticle delivery.
Nanoparticles
The use of nanoparticles in drug and gene delivery is rapidly gaining popularity. Although
strictly defined by the National Cancer Institute as any particle with at least one dimension
under 100 nm, in this review the term nanoparticle will be used to define any sub-micron
vehicle, often capable of carrying a therapeutic payload. Nanoparticles vary in shape and
size, along with physical and therapeutic properties. Some common types of nanoparticles
are micelles, liposomes, dendrimers, solid nanoparticles, emulsions, and microemulsions,
which are detailed extensively in [34, 36, 37]. Nanoparticles are often exploited as delivery
vehicles by encapsulating a therapeutic compound that may otherwise cause systemic
toxicity if delivered in free form. Many nanoparticle delivery vehicles show promise for
carrying high therapeutic payloads, controllable release rates, and targeting abilities – both
passive and active [38]. By simply altering surface properties, various aspects of the in-vivo
performance can be modified [39].
In cancer therapy the small size of nanoparticles is particularly advantageous within tumor
vasculature. Solid tumors incite blood vessels with larger diameters and increased
permeability [40]. In many tumors, the vessels are leaky, with inter-endothelial gaps an
average of 380-780 nm, but with some as large as over 1 μm depending on tumor type and
location [41]. Furthermore, high pressure and low lymphatic drainage in tumors decreases
the clearance of high molecular weight nanoparticles from the tumor interstitium [42]. These
abnormal properties in combination form the enhanced permeability and retention (EPR)
effect which permits increased retention of nanoparticles in tumors [43, 44]. Because typical
nanoparticle sizes prevent extravasation from normal vasculature, they are passively targeted
to tumor tissue.
Nanoparticles and Ultrasound
Although the subject is beyond the scope of this review, ultrasound alone has been shown to
improve nanoparticle delivery through thermal or mechanical processes. Ultrasonic heating
can cause direct effects on the tissue itself by changing blood flow and vascular pressure, or
can activate an agent such as a thermally sensitive nanoparticle or nanodroplet [20, 45]. The
use of ultrasound and nanoparticles has also gained interest in the field of dentistry. High
intensity focused ultrasound (HIFU) has been shown to aid in delivery of antibacterial
agents into dentinal tubules by inducing cavitation [46, 47].
In the field of therapeutic ultrasound with microbubbles, the most commonly used types of
nanoparticles are quantum dots [48], liposomes [49-52], and poly(lactic-co-glycolic acid)
(PLGA) nanoparticles [53, 54]. Quantum dots are often used in studies in place of
nanoparticle drugs to characterize delivery vehicles and evaluate successful delivery into
targeted tissue. Doxorubicin-containing liposomes have been used extensively in ultrasound
and microbubble delivery studies (see Table 1). One reason for their popularity in research
studies is that several forms, known as Doxil or Caelyx, DaunoXome and Myocet , are
already FDA approved for use in the clinic. Doxorubicin is also inherently fluorescent,
which makes optical tracking of delivery feasible. Another form of liposome used with
microbubble ultrasound delivery is the lipoplex, which is a liposome containing genetic
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material such as plasmid DNA [55-57]. This method protects the DNA during in-vivo
circulation and allows a higher amount of genetic material to be delivered [55, 56].
Mechanisms
Ultrasound exposure in the presence of microbubbles can increase both cellular and vascular
permeability, leading to enhanced nanoparticle delivery. An increase in cell permeability
ensues from the formation of pores in the cell membrane during a process called
sonoporation. At higher pressures, ultrasound alone can cause the formation of pores within
the cell membrane [58]. This effect is enhanced with the addition of microbubbles. Although
the exact mechanisms are not fully understood, the oscillation of microbubbles in an
ultrasound field creates transient pores in the lipid bilayer [59-61]. The degree of
sonoporation is dependent on the cavitation behavior of the microbubbles, which is in turn
dependent on the acoustic conditions applied. Both stable and inertial cavitation have been
shown to result in pore formation [1, 28]. During stable cavitation, the microbubble
oscillates without disruption, whereas during inertial cavitation, the microbubble is unstable
and fragments [1]. Streaming of fluid around the bubble can occur in both cases and causes
shearing of the cellular membrane [62, 63]. When microbubbles near cellular membranes
are exposed to high energy pulses they often form microjets during collapse, resulting in
high shear stresses from streaming and shockwaves that are thought to lead to pore
formation [64, 65]. Along with creating openings in cells, the cavitation response of
microbubbles may also facilitate uptake by forcing the nanoparticles into the cell through
microjets [66].
Pore formation can be either transient (reversible) or permanent. Transient pore formation
has been observed in-vitro wherein pores remained open for seconds to hours. In some
instances, pore openings have been reported up to 24 hours after ultrasound exposure [67].
Permanent pore formation is undesirable in most applications, as it leads to cell death.
Consequently, care must be taken in selecting appropriate acoustic conditions as cell death
can occur with sufficiently high or long ultrasound exposure [62, 63, 68]. For example,
Deng et al. observed an increased transmembrane current in cells subjected to both
ultrasound and the presence of microbubbles indicating increased membrane porosity[69].
Cells recovered to resting levels in about 4 to 10 seconds following insonation for
approximately one second at 1 MHz and 1 MPa pressure, but higher ultrasound intensities (>
1 MPa), resulted in irreversible cell damage and cell death. In general, reagent delivery
increases with increasing acoustic pressure, but so too does the likelihood of cell apoptosis
[68-72].
Many groups are also investigating cellular changes that occur as a result of ultrasound
exposure, including changes in calcium levels, cell signaling pathways, and endocytosis [60,
73]. In a study on gene delivery to BLM melanoma cells, Lentacker et al. found that
lipoplexes were directly entering the cell cytoplasm through sonoporation rather than
endocytosis[56]. The uptake was seen to occur during or immediately after ultrasound
exposure. Meijering et al. also observed small molecules (4.4 kDa and 70 kDa) entering the
cell membrane via pores, however they found that larger molecules (155 kDa and 400 kDa)
were entering into the cell through vesicle formation in endocytosis [60]. The role of
calcium in sonoporation has been investigated and is believed to aid in cell recovery after
pore formation [74]. Other cellular changes that have been observed are hyperpolarization of
the cell membrane, release of free radicals, and increased levels of hydrogen peroxide [74,
75]. Yang et al. recorded differences in cell viability and permeability depending on the
stage of cell growth, indicating the cell cycle may play a role in cell permeability [74].
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With respect to vessel permeability, effects can range from mild reversible permeability
enhancement to gross vessel rupture, depending on the microbubble and acoustic parameters
[76-80]. Results from many groups have suggested that large molecules (such as dextrans),
as well as nanoparticles, enter into the interstitial space after sonication with microbubbles
[81-84]. This vascular permeability is expected to be a result of the interaction between
microbubbles and vessel walls. Caskey et al. studied the effects of insonated microbubbles
within ex-vivo vessels and observed both asymmetric collapse and jet formation near the
vessel wall [85]. Chen et al. also studied microbubbles within ex-vivo vessels and observed
that jet formation occurs away from the vessel wall [86-88].
Acoustic radiation force also enhances nanoparticle delivery. Radiation force, or the
Bjerknes force, refers to the directional forces experienced by objects in an ultrasound field.
Due to the transfer of momentum from the sound wave to the bubble, bubbles are translated
in the direction of the acoustic wave propagation [89, 90]. In order to achieve translation,
radiation force pulse sequences require a high duty cycle which is low in amplitude so as to
not rupture the microbubbles. Radiation force applied perpendicularly to vessel orientation
can result in microbubbles being pushed to the vessel walls, where they can accumulate
[91].The phenomena has been shown to aid in delivery of nanoparticles when microbubbles
are used [49, 93-95]. When nanoparticles are attached to the microbubble, local
concentration of nanoparticles can be increased by pushing the microbubbles against the
vessel wall in one location [91, 92, 96].
Types of administration
There are two main administration methods employed for nanoparticle delivery with
ultrasound and microbubbles: un-bound and bound nanoparticles. In the first method, the
nanoparticles are not associated with the microbubbles, but are either injected separately co-
administered. If separate injections are performed, the order of injection may vary as long as
microbubbles are present when ultrasound is applied. Lin et al. showed no significant
difference in tumor accumulation between quantum dot injected before or after insonation as
long as microbubbles were present during the ultrasound [97].
The second method of delivery requires the nanoparticles to be attached to the microbubble
prior to injection and ultrasound treatment. There are numerous ways to associate the
nanoparticle with the microbubble. One of the most common methods to attach a
nanoparticle to the microbubble is through biotin-avidin interactions. Biotinylated
microbubbles are used to attach either avidin or streptavidin nanoparticles, or in some cases
an avidin linker is used to link biotinylated particles [49, 52]. Although biotin-avidin linkage
is suitable for proof of concept studies, it is not ideal for in-vivo use because it can induce an
immunogenic response [49, 98]. An alternative to this method is to use maleimide-thiol
chemistry. Maleimide conjugation is often used in molecular imaging studies to create
targeted microbubbles, and can also be applied to nanoparticle attachment to the shell of the
microbubble [51]. Another covalent binding possibility is illustrated by Burke et al. where
PLGA nanoparticles were coupled to albumin microbubbles through carbodiimide chemistry
[53]. Oligonucleotides have also been employed as tethers to link vesicles to microbubbles
through hybridization of complementary lipid-linked DNA oligonucleotides [99].
Electrostatic binding of nanoparticles to microbubbles is often implemented in gene delivery
studies wherein negatively charged DNA is attached to positively charged microbubbles
with shells composed of a cationic lipid. Electrostatic interactions can also be exploited to
create nanoparticle-bound microbubbles. One example of this was described by Seo et al.
who created positively charged monodisperse microbubbles through microfluidics and
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attached negatively charged silica coated nanoparticles [100]. This technique was shown to
be effective for various sizes and shapes of nanoparticles.
Drugs can also be directly incorporated into the shell of the microbubble, although this
provides a challenge in the inherently limited payload capacity. Drug-loaded polymer
shelled microbubbles, whose thicker shells allow for higher drug loading, fragment into
“nanoshards”, which are less than 400nm [101-103]. These shards are small enough to
extravasate from the vasculature of the tumor.
There are some definite advantages to linking the nanoparticle to the microbubbles. Along
with being able to track the nanoparticle in circulation by ultrasound imaging of the
microbubble carriers, attaching the nanoparticle ensures that they are present at the target
site during insonation. Using ultrasound to rupture the microbubble at a desired location
leads to targeted deposition of particles. As discussed earlier, linking the nanoparticle to the
microbubble also allows for radiation force to be used to increase particle/drug
concentration at the desired site. Lum et al. and Kheirolomoom et al. demonstrated higher
delivery of nanoparticles in-vitro using radiation force in combination with microbubble-
loaded nanoparticle constructs compared to without using radiation force [49, 93]. Linking
nanoparticles to microbubbles is also advantageous because it prevents dilution of the
nanoparticle solution when it enters the bloodstream [53]. Finally, microbubbles loaded with
certain nanoparticles may serve as multi-modality contrast agents for platforms such as dual
MRI-ultrasound and optical-ultrasound [104-106], although further discussion of these is
beyond the scope of this review.
There are also some challenges related to associating the nanoparticle to the shell. When
linking through a process such as biotin and avidin, multiple washing steps are necessary to
remove free linking agent. This can be both time consuming and detrimental to the fragile
bubble preparation, requiring a higher initial concentration of microbubbles. Furthermore,
excess nanoparticles are typically required to maximize loading. Finally, attaching the
nanoparticle to the microbubble may alter the in-vivo circulation time and biodistribution.
This is discussed further in the last section of our review.
Ultrasound Setup
There are a variety of ultrasound systems in use to accomplish microbubble-aided
nanoparticle delivery. Many researchers use single element transducers powered by arbitrary
waveform generators and amplifiers, whereas others use commercial therapy systems or
even clinical imaging systems (Table 1). In [107], Seip et al. describe ideal qualities of a
therapy system, including the ability to both image and treat a desired location in order to
monitor delivery and release of the agent. The system should be able to generate intensities
and pulse sequences needed for microbubble delivery, deliver focused energy deep within
tissue to target a specific area, treat in an acceptable amount time, be incorporated into
current treatment workflow, and be easy to use and set up. Most therapeutic treatments
involve ultrasound with a center frequency around 1 MHz, which is much lower than
clinical imaging systems typically provide. Although some custom systems have been
created, dual imaging and treatment often requires multiple transducers to be used in
conjunction with one another [108]. Nanoparticle delivery has been performed with both
focused and unfocused transducers, as well as at varying pressures – up to 7MPa (Table 1).
Successful Nanoparticle Delivery Studies
Some of the first nanoparticle delivery studies were performed in-vivo with fluorescent
nano/microspheres (100- 500 nm) delivered to rat skeletal muscle [81, 109]. In these studies,
vessel rupture caused by microbubble breaking was observed, and the particles were
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delivered into the intersitium of the muscle. Extravasation points were observed where
particles and red blood cells leaked out of the vasculature (Fig 1). Findings also illustrated
the importance of allowing microbubbles to replenish in between ultrasound pulses and
quick (10 s) injection of particles to increase deposition. Delivery of fluorescent nanospheres
(30-120 nm) to cardiac muscle was later shown by Vancraeynest et. al [82].
Feasible in-vivo nanoparticle drug delivery with microbubbles and ultrasound was
demonstrated with fibroblast growth factor-2 loaded PLGA nanoparticles [110]. Initial
studies depicted 40 fold and 670 fold increases in nanoparticle delivery to the mouse
adductor muscle when ultrasound or ultrasound and microbubbles were applied compared to
nanoparticles alone. Subsequently, drug loaded nanoparticles were delivered into the
ischemic hind limb of the mouse with the addition of ultrasound and microbubbles. Results
of the studies showed an increase in total number of large and moderate diameter arterioles,
as well as marked luminal expansion of pre-existing collateral arteries and transverse
arterioles. Although the growth factor did not induce angiogenesis in gracilis muscles,
arteriogenic remodeling was seen along with an increase in arteriole-line intersections (Fig
2).
Successful nanoparticle gene delivery was demonstrated in-vitro with plasmid DNA
(pDNA), short interfering RNA (siRNA) and messenger RNA (mRNA), often involving a
fluorescently tagged gene so that transfection can be easily quantified [55-57, 111, 112].
Encapsulating the genetic material within a liposome, creating a lipoplex, or siPlex, protects
the genetic material and allows more to be delivered to the target site. Ultrasound mediated
delivery with microbubbles was found to overcome the limitations of PEGylated liposomes.
Although PEG increases circulation of the lipo/siPlexes, it hinders cellular uptake. When
cells in an Opticell were exposed to ultrasound, liposomes loaded with up to 15mol% PEG
had limited gene expression/inhibition with free liposomes, but exposure to loaded
microbubbles and ultrasound led to statistically significant differences (Fig 3, 4). These
studies also demonstrated the direct entry of liposomes into the cytoplasm when ultrasound
and microbubbles are present [56]. Uptake and expression was investigated further with
mRNA lipoplexes loaded on to microbubbles [57]. Uptake was observed in 50% of the cells
when loaded microbubbles and ultrasound were applied, compared to 0% uptake with
lipoplexes alone, and 24% of the cells illustrated successful transfection. These results
support the hypothesis that not all of the contents are released from liposomes upon
insonation.
Liposomal loaded microbubbles have also proven to be advantageous for drug delivery. As
mentioned in an earlier section, Doxil, and other doxorubicin containing liposomes are
commonly used in ultrasound and microbubble delivery studies. When doxorubicin-
containing liposomes were bound to microbubbles and delivered to melanoma cells in an
Opticell, significantly higher cytotoxicity was seen (Fig 5)[113]. Additional findings
indicated that enhanced delivery was caused by both release of doxorubicin from liposomes
and sonoporation caused by the microbubbles. The released free doxorubicin enters into the
cell more efficiently than the liposome contained doxorubicin. Studies carried out with self-
assembling liposome loaded microbubbles revealed a lower dose of doxorubicin could be
used when the liposomes were bound compared to free liposomes [51].
Recently, enhanced in-vivo delivery of liposomal doxorubicin has also been observed. After
several studies with lipid coated quantum dots delivered in mice, studies were carried out
with Doxil and microbubbles with ultrasound exposure [114]. The concentration of Doxil in
tumor tissue over time, the impact on tumor size on various treatments, and dose were
investigated. Using focused ultrasound, more Doxil was delivered when microbubbles were
administered, and colorectal adenocarcinoma tumor growth in mice was hindered (Fig 6). At
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24 hours after treatment, more drug was concentrated within the tumor compared to
treatments of Doxil alone, however, the concentrations of both treatments were similar by 48
hours. It was also observed that smaller tumors responded better to treatment than larger
tumors at 5 mg/kg. Larger tumors required a higher treatment dose of 10 mg/kg. Tumor
histology revealed extravasation of fluorescent Doxil (Fig 7).
Delivery of doxorubicin-containing nanoshards has also been carried out in-vivo. Polymer
microbubbles containing doxorubicin in the shell were destroyed within VX2 tumor bearing
rabbits, which created nanoshards capable to extravasating into tumor tissues. Initial studies
revealed significantly higher concentration of doxorubicin within the periphery of the tumor
following ultrasound treatment compared to no insonation [102]. In later work, significant
differences in tumor growth were also observed between mice treated with drug loaded
microbubbles and ultrasound compared to free drug at 14 days (Fig 8) [115]. Paclitaxel
loaded polymer microbubbles are also being developed which can hold up to 20 times as
much drug as doxorubicin loaded microbubbles [101].
Nanoparticle drug delivery has also recently been applied to fields outside of chemotherapy
[116]. Microbubbles loaded with rapamycin coated magnetic ion nanoparticles are being
investigated as a treatment option for ischemic coronary heart disease. Using magnetic
stents, the nanoparticle loaded microbubbles are targeted to the desired location, and then
the drug is released when the microbubbles are ruptured using ultrasound. In-vitro studies
have shown cell growth inhibition with rapamycin loaded nanoparticles, while testing of the
magnetic stents confirms microbubble accumulation at the stent. Increasing the flow
conditions lead to an increase in nanoparticle deposition.
Considerations
There are still many obstacles to overcome to translate microbubble mediated ultrasound
delivery of nanoparticles into a clinical setting, but progress is being made as more in-vitro
and in-vivo studies are being performed. Work remains to be done on understanding the
mechanisms taking place in-vivo in order to ensure that safe delivery can be achieved.
Bioeffects will need to be closely monitored as tissue damage has been seen in some studies
[82]. It will also be important to understand the biodistribution and pharmacokinetics of the
nanoparticles when delivered with microbubbles. As discussed in [52], liposome
nanoparticles generally have long circulation times, but when bound to microbubbles the
complex is limited to the 5-10 minute circulation time of the microbubble. Although the
microbubble mediated delivery method will increase the nanoparticle concentration at the
target site, accumulation in other organs is always a major factor to consider, as drug or gene
accumulation in non-targeted organs/tissues could be detrimental. For example, unlike with
liposomes, a high concentration of lipid from circulating microbubbles is taken up by the
spleen. Nanoparticles bound to the microbubble may therefore also end up in the spleen.
Another area that is actively under investigation is the effect of ultrasound on the integrity of
the nanoparticle, and how bound nanoparticles disassociate from microbubbles. There have
been conflicting reports about how and if the nanoparticle is released from the shell. Lum et
al. detected lipid labeled with DiI on the nanoparticles after breaking the microbubble [93].
However, other groups have found that the nanoparticle breaks free [49, 55, 112].
Ultrasound exposure has also been shown in some cases to cause release of the contents [52,
113], whereas in other studies the cargo remains intact within the liposome carriers [111,
112].
Loading optimization also needs to be addressed. Loading estimates of liposomes onto
microbubbles have been between 600 and 10000 liposomes per microbubble, depending on
the size of both the microbubble and the liposome [49, 51, 52]. This may be complicated
Mullin et al. Page 7













further by the fact that lipids are not uniformly distributed through the shell layer of
microbubble, resulting in heterogeneous loading of nanoparticles [93, 117]. Uniform loading
is desirable in order to accurately quantify the amount of drug or gene on each bubble, and
therefore delivered to the target site. Optimization of loading is challenging because it is
frequently difficult to determine concentrations of nanoparticle solutions due to their small
size. Although binding can be confirmed through methods such as flow cytometry, UV
spectrometry, and microscopy, exact numbers of bound nanoparticles are difficult to obtain.
Further optimization of both ultrasound settings and delivery vehicle design are also needed.
Because a variety of systems exist which deliver ultrasound energy, there is also a wide
range of settings in use. Currently, comparisons between studies are hard to make because of
the highly-variable acoustic parameters used from study to study. Aside from ultrasound
systems and settings, different microbubble formulations and nanoparticles are used that
influence the results of each study. Further refining of microbubble populations through size
selection techniques may be a way to improve the effectiveness of delivery methods.
Microbubble populations with high uniformity in size may allow optimal loading of
particles onto the shell along with a better prediction of the microbubble response to
ultrasound [119]. Additionally, further study of the tradeoffs between bound and free
nanoparticle delivery are needed for each application.
Despite the challenges being faced in the field of nanoparticle delivery, many advances are
being made with the use of ultrasound and microbubbles, and the approach is developing
into a promising method to improve treatments in cancer and genetic disorders.
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Discrete extravasation points created by the application of 1 MHz ultrasound to
microbubbles flowing through skeletal muscle capillaries. Several extravasation points are
highlighted with arrows in B.The specimen is from treatment group C [microbubble
injection site: carotid artery, 40s injection, 5 s pulsing interval, 8 ultrasound pulses]. The
bars indicate 1 mm. Reprinted from Journal of the American College of Cardiology, 39/4,
Song J, Chappell JC, Oi M, VanGieson EJ, Kaul S, Price RJ, “Influence of injection site,
microvascular pressure and ultrasound variables on microbubble-mediated delivery of
microspheres to muscle”, 726-731, (2002), with permission from Elsevier.
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The delivery of FGF-2bearing nanoparticles by ultrasonic microbubble destruction elicits
arteriogenic remodeling in gracilis adductor muscle. A–D: Representative whole-mount
images of fluorescently-labeled SM α-actin+ vessels in gracilis adductor muscles 7 and 14
days after FGF-2 (A and B) and BSA (C and D) treatment. Note the significant increase in
arteriolar caliber and density in FGF-2-treated muscles. E: Bar graph of arteriole-line
intersections at both time points for FGF-2, BSA, and sham surgery treatment. Values are
means with standard errors. *indicates significantly different (P<0.05) than BSA and sham
surgery at day 14. Reprinted from [110], with permission from John Wiley & Sons Inc.
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Figure 2. (A) Schematic representation of the experimental setup. Cells were grown on one
side of an Opticell unit. For ultrasound exposure, Opticell plates were turned upside down.
In this way, microbubbles were able to rise against the cell layer. (B) The transfection
efficiency of lipoplex loaded microbubbles in the presence of ultrasound (black bars)
compared to the transfection efficiency of naked DNA and free 15 mol % PEGylated
lipoplexes in the absence (light gray bars) and presence of microbubbles and ultrasound
(dark gray bars). The background luciferase signal in untreated cells is also shown (white
bars). The transfection results, i.e., the extent of luciferase expression, are expressed as RLU
(RLU: relative light units) per mg protein. *p < 0.05. Reprinted with permission from [56].
Copyright (2009) American Chemical Society.
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Silencing efficiency of free siPlexes and PEG-siPlexes in the absence and presence of
ultrasound, and PEG-siPlex loaded microbubbles in the presence of ultrasound. The
PEGylation (DSPE-PEG2000-biotin) degree of the siPlexes is represented in the x-axis. The
black and the dark grey bars represent the gene silencing efficiency of free siPlexes in the
absence and presence of ultrasound, respectively. The light grey and white bars represent the
gene silencing of the siPlexes loaded on the microbubbles in the absence or presence of
ultrasound. In all cases, the following ultrasound settings were used: 1 MHz, 10% DC, 2W/
cm2, 10 s. The results are expressed as percentage of luciferase expression compared to
mock siRNA transfected cells. The asterisks (*) represent significant differences with
p<0.05. (MB = microbubble; US = ultrasound). Reprinted from Journal of Controlled
Release, 126/3, Vanderbroucke RE, Lentaker I, Demeester J, De Smedt SC, Sanders NN,
“ Ultrasound assisted siRNA delivery using PEG-siPlex loaded microbubbles”, 265-273,
(2008), with permission from Elsevier.
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Cell viability of the melanoma cells after treatment with DOX-liposomes without (light gray
bars) and with ultrasound exposure (USE) (dark gray bars) and DOX-liposome-loaded
microbubbles after ultrasound exposure (white bars) as a function of the DOX concentration
in the OptiCell. For higher doxorubicin concentrations, more doxorubicin liposomes were
used, whereas the microbubble concentration was always 109 microbubbles per OptiCell
unit. *P < 0.05.DOX, doxorubicin. Reprinted by permission from Macmillan Publishers Ltd:
Molecular Therapy, [113], copyright (2009).
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Effect of initial size of treated tumors on the tumor growth response for the treatments with
5 mg/kg of DOX. The arrows indicate the schedule for treatments. (A) and (B) are the tumor
growth responses for an initial size of treated tumors ≤30 mm3 and ≥100 mm3, respectively.
N = 5 for each group, mean ± SD, and *P <0.05 (Mann-Whitney U test). Reprinted from
Nanomedicine: Nanotechnology Biology and Medicine, Lin C-Y, Li J-R, Tseng H-C, Wu
M-F, Lin W-L , “Enhancement of focused ultrasound with microbubbles on the treatments
of anticancer nanodrug in mouse tumors”, 1-8, (2011), with permission from Elsevier.
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Accumulation of DOX in the tumor tissues at 1, 3, 6, 12, 24 and 48 h after treatments. (A)
shows the calibration curve illustrating the relationship between DOX concentration and
fluorescent intensity at 582 nm; (B) shows the DOX extracted from the tumor tissues treated
with DOX or MBs+FUS+DOX (5mg/kg of DOX injected and *P<0.05 at 24 h after
treatments); (C) representative fluorescent images showing the DOX deposition (red, white
arrow) related to CD31-stained blood vessels (green) at 24 h after treatments (magnification:
400×). N = 3 for each case. Reprinted from Nanomedicine: Nanotechnology Biology and
Medicine, Lin C-Y, Li J-R, Tseng H-C, Wu M-F, Lin W-L , “Enhancement of focused
ultrasound with microbubbles on the treatments of anticancer nanodrug in mouse tumors”,
1-8, (2011), with permission from Elsevier.
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Effect of vehicle on tumor growth in rats. Vehicles include; 12 mg UCA , 12 mg
nanoparticles , a combination of 6 mg nanoparticles and 6 mg UCA , or free doxorubicin
. All rats were insonated for 20 minutes after injection. Tumors treated with UCA did not
show a significant increase in size over 14 days (P = .3) and had significantly less growth
than rats treated with free doxorubicin after 14 days (P = .0390). Reprinted from Academic
Radiology, 18/11, Cochran MC, et al., “Disposition of ultrasound sensitive polymeric drug
carrier in a rat hepatocellular carcinoma model, 1341-1348,(2011), with permission from
Elsevier.
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